PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU

Zacks01-14

Insulet Corporation PODD recently made its Omnipod 5 automated insulin delivery system commercially available in five more countries, Italy, Denmark, Finland, Norway and Sweden. Omnipod 5 is available...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2503579614?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 20:51","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2503579614","market":"us","top_or_hot":-1,"title":"PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU","media":"Zacks","content":"<div>\n<p>Insulet Corporation PODD recently made its Omnipod 5 automated insulin delivery system commercially available in five more countries, Italy, Denmark, Finland, Norway and Sweden. Omnipod 5 is available...</p>\n\n<a href=\"https://finance.yahoo.com/news/podd-stock-gains-launch-omnipod-125100017.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-14 20:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/podd-stock-gains-launch-omnipod-125100017.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Insulet Corporation PODD recently made its Omnipod 5 automated insulin delivery system commercially available in five more countries, Italy, Denmark, Finland, Norway and Sweden. Omnipod 5 is available...</p>\n\n<a href=\"https://finance.yahoo.com/news/podd-stock-gains-launch-omnipod-125100017.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2177674079.SGD","symbol_name":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","start_time":0,"source_url":"https://finance.yahoo.com/news/podd-stock-gains-launch-omnipod-125100017.html","article_id":"2503579614","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503579614","pubTimestamp":1736859060,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Insulet Corporation PODD recently made its Omnipod 5 automated insulin delivery system commercially available in five more countries, Italy, Denmark, Finland, Norway and Sweden. Omnipod 5 is available with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring  sensor compatibility.The latest development represents a significant step forward in expanding access to its innovative, tubeless Omnipod 5 automated insulin delivery  system for more people.Omnipod 5 is the first and only tubeless AID system indicated for individuals aged two years and older with type 1 diabetes. Omnipod 5 System simplifies diabetes management and has shown an improvement in results by removing the need for multiple daily injections therapy along with automatically adjusting insulin delivery every five minutes using its advanced SmartAdjust technology.Omnipod 5 is recognized as the number one insulin pump for new pump users in Europe. Omnipod 5 is also the number one prescribed AID sys","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","PODD":"银休特","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4566":"资本集团","VCYT":"Veracyte Inc","OMCL":"Omnicell","RMD":"瑞思迈","BK4167":"医疗保健技术","BK4082":"医疗保健设备","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","BK4588":"碎股","RMD.AU":"Resmed DRC","BK4551":"寇图资本持仓","BK4156":"煤与消费用燃料","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓"},"translate_title":"Omnipod 5在欧盟五个国家推出，PODD股票上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1,"RMD":1,"PODD":1,"OMCL":1,"RMD.AU":0.9},"content_text":"Insulet Corporation PODD recently made its Omnipod 5 automated insulin delivery system commercially available in five more countries, Italy, Denmark, Finland, Norway and Sweden. Omnipod 5 is available with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (“CGM”) sensor compatibility. \nThe latest development represents a significant step forward in expanding access to its innovative, tubeless Omnipod 5 automated insulin delivery (“AID”) system for more people.\nPODD Stock’s Likely Trend Following the News\nFollowing the announcement on Jan. 14, PODD’s shares climbed 0.7% to $270 at yesterday’s after-market trading session. The company’s solid innovation efforts and ongoing expansion of the Omnipod 5 platform are solidifying its market leadership. We expect the market sentiment toward PODD stock to remain positive surrounding this development.\nInsulet has a market capitalization of $18.80 billion at present. Going by the Zacks Consensus Estimate, the company’s earnings are likely to increase 17.1% in 2024 on 21.2% improvement in revenues. In the trailing four quarters, it delivered an earnings beat of 52.4%, on average.\nAbout Insulet’s Omnipod 5\nOmnipod 5 is the first and only tubeless AID system indicated for individuals aged two years and older with type 1 diabetes. Omnipod 5 System simplifies diabetes management and has shown an improvement in results by removing the need for multiple daily injections therapy along with automatically adjusting insulin delivery every five minutes using its advanced SmartAdjust technology. \nOmnipod 5 is recognized as the number one insulin pump for new pump users in Europe. Omnipod 5 is also the number one prescribed AID system in the United States and the first tubeless, waterproof AID system with proactive glucose control designed to deliver exceptional ease of use. \nGrowing Presence of Insulet’s Omnipod 5\nOmnipod 5 was first introduced in the United States in 2022 and has demonstrated strong clinical results with real-world evidence, including lower A1c and improved time in range while maintaining low time in hypoglycemia. In 2023, after the successful launch of Omnipod 5 in the United Kingdom and Germany, Insulet introduced Omnipod 5 in France, one of its largest markets, and the Netherlands in June 2024. \nIndustry Prospects Favoring Insulet\nPer a report from Grand View Research, the global diabetes devices market was valued at $30.31 billion in 2023 and is expected to witness a compound annual rate of 7.5% through 2030. The market is mainly driven by the growing prevalence of diabetes, the rising usage of insulin-delivery devices and high obesity rates. The market is characterized by a high degree of innovation, focusing on creating solutions for more accurate and efficient diagnosis and treatment.\nImage Source: Zacks Investment Research\nOther Developments by Insulet\nIn November 2024, Insulet made its Omnipod 5 AID system compatible with Abbott’s FreeStyle Libre 2 Plus CGM sensor in the United States. In October 2024, the company made the full market release of the Omnipod 5 App for iPhone in the United States. The app offers unique capabilities, such as a Custom Foods feature that allows users to input, save and list carbohydrate counts for their typical meal sizes, favorite foods and snacks.\nPODD Stock’s Price Performance\nIn the past year, Insulet’s shares have risen 33.7% compared with the industry’s growth of 7.8%.\nPODD’s Zacks Rank and Key Picks\nInsulet currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Veracyte VCYT, ResMed RMD and Omnicell OMCL.\nVeracyte, carrying a Zacks Rank of #1 (Strong Buy) at present, has an estimated earnings growth rate of 65.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.\nVCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.\nResMed, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 21.1% for 2025. RMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year. \nOmnicell, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 72.7% for fourth-quarter 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%. OMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nOmnicell, Inc. (OMCL) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nInsulet Corporation (PODD) : Free Stock Analysis Report\nVeracyte, Inc. (VCYT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2503579614"}